title: Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease.
abstract: OBJECTIVE
  To evaluate the cost-effectiveness of enzyme replacement therapy (ERT) compared to standard medical care without ERT in the Dutch cohort of patients with type 1 Gaucher disease (GD I).
  
  
  METHODS
  Cost-effectiveness analysis was performed using a life-time state-transition model of the disease's natural course. Transition probabilities, effectiveness data and costs were derived from retrospective data and prospective follow-up of the Dutch study cohort.
  
  
  METHODS
  The tertiary referral center for Gaucher disease in the Netherlands.
  
  
  METHODS
  The Dutch cohort of patients with GD I.
  
  
  METHODS
  ERT versus standard medical care without ERT in symptomatic patients.
  
  
  METHODS
  Years free of end organ damage (YFEOD) (splenectomy, bone complication, malignancy, multiple complications), quality adjusted life years (QALY), and costs.
  
  
  RESULTS
  Over an 85 year lifetime, an untreated GD I patient will generate 48.9 YFEOD and 55.86 QALYs. Starting ERT in a symptomatic patient increases the YFEOD by 12.8 years, while the number of QALYs gained increases by 6.27. The average yearly ERT medication costs range between € 124,000 and € 258,000 per patient. The lifetime costs of ERT starting in the symptomatic stage are € 5,716,473 against € 171,780 without ERT, a difference of € 5,544,693. Consequently, the extra costs per additional YFEOD or per additional QALY are € 434,416 and € 884,994 respectively. After discounting effects by 1.5% and costs by 4% and under a reasonable scenario of ERT unit cost reduction by 25%, these incremental cost-effectiveness ratios could decrease to € 149,857 and € 324,812 respectively.
  
  
  CONCLUSIONS
  ERT is a highly potential drug for GD I with substantial health gains. The conservatively estimated incremental cost-effectiveness ratios are substantially lower than for Pompe and Fabry disease. We suggest that the high effectiveness has contributed importantly to acceptance of reimbursement of ERT for GD I. The present study may further support discussions on acceptable price limits for ultra-orphan products.
authors.forename: Laura
authors.initials: L
authors.lastname: van Dussen
authors.forename: Marieke
authors.initials: M
authors.lastname: Biegstraaten
authors.forename: Carla E M
authors.initials: CE
authors.lastname: Hollak
authors.affiliation: Clinical Research Unit, Academic Medical Center, PO Box 22660, 1100 DD Amsterdam, The Netherlands. m.g.dijkgraaf@amc.uva.nl.
authors.forename: Marcel G W
authors.initials: MG
authors.lastname: Dijkgraaf
mesh_terms: D056947:Enzyme Replacement Therapy / Q000191:economics*; D005260:Female; D005776:Gaucher Disease / Q000188:drug therapy* / Q000191:economics*; D006801:Humans; D008297:Male; D009426:Netherlands; D011446:Prospective Studies; D012189:Retrospective Studies; D016896:Treatment Outcome
references.citation: Health Technol Assess. 2012;16(39):1-543
references.pmid: 23089251
references.citation: Qual Life Res. 1997 Mar;6(2):169-84
references.pmid: 9161117
references.citation: Blood Cells Mol Dis. 2011 Jan 15;46(1):111-4
references.pmid: 20542712
references.citation: Orphanet J Rare Dis. 2013 Feb 19;8:29
references.pmid: 23421808
references.citation: J Inherit Metab Dis. 2008 Jun;31(3):337-49
references.pmid: 18404411
references.citation: Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136
references.pmid: 16796930
references.citation: Pharmacoeconomics. 2001;19(11):1091-102
references.pmid: 11735676
references.citation: CMAJ. 2001 Sep 4;165(5):595-6
references.pmid: 11563212
references.citation: Blood Cells Mol Dis. 2011 Jan 15;46(1):107-10
references.pmid: 20684886
references.citation: Mol Genet Metab. 2002 Sep-Oct;77(1-2):91-8
references.pmid: 12359135
references.citation: Med Care. 1997 Nov;35(11):1095-108
references.pmid: 9366889
references.citation: Orphanet J Rare Dis. 2011 Apr 16;6:16
references.pmid: 21496291
references.citation: ANZ J Surg. 2008 Mar;78(3):204-10
references.pmid: 18269491
references.citation: QJM. 1996 Sep;89(9):691-4
references.pmid: 8917744
references.citation: BMJ. 2005 Aug 20;331(7514):446-8
references.pmid: 16110075
references.citation: Blood Cells Mol Dis. 2006 Jan-Feb;36(1):53-8
references.pmid: 16246599
references.citation: Cancer. 1993 Jul 1;72(1):219-24
references.pmid: 8508410
references.citation: Pharmacoeconomics. 1998 Apr;13(4):397-409
references.pmid: 10178664
references.citation: Health Econ. 2006 Oct;15(10):1121-32
references.pmid: 16786549